Published by Global Banking & Finance Review®
Posted on June 3, 2025
2 min readLast updated: January 23, 2026
Add as preferred source on GoogleHims acquires UK startup Zava to expand in Europe, entering Germany, France, and Ireland. The move adapts to US regulatory changes on Wegovy.
By Bhanvi Satija
NEW YORK (Reuters) -Telehealth platform Hims & Hers said on Tuesday it will acquire London-based startup Zava for an undisclosed amount, allowing it to launch its offerings in Germany, France and Ireland and reach more international patients.
The move comes as Hims is adjusting to a regulatory ban in the United States on manufacturing mass copies of Novo Nordisk's popular weight-loss drug Wegovy, that took effect on May 22. Hims began offering copies of Wegovy in 2024, and saw a boost in its revenues, when the branded version of the highly in-demand drug was in shortage.
The telehealth firm's shares, which have dropped nearly 9% in the last two weeks, rose 6.15% to $60.26 in premarket trading.
It recently entered into an agreement with Novo to help patients access brand-name Wegovy, and plans to enter the market for low testosterone and menopause treatments in pursuit of new growth opportunities.
Hims did not provide financial terms of the deal, but a company spokesperson said these details will be shared with its second-quarter results expected in August.
It plans to fund the acquisition through cash on its balance sheet at closing. The deal is expected to close in the second half of this year.
Backed by equity firm HPE Growth, Zava provides medical consultations and delivery of prescription medicines — including weight-loss drugs Mounjaro and Wegovy — to its more than 1 million customers across United Kingdom, Germany, France and Ireland.
Hims said it plans to introduce personalized skin care, weight loss and other offerings for patients in these markets and will introduce an option for patients to interact with their healthcare providers in local languages.
Last week, Hims also said it will cut about 4% of its workforce but still plans to hire for roles related to its long-term growth strategy.
(Reporting by Bhanvi Satija in New York, additional reporting by Sriparna Roy in Bengaluru; Editing by Lincoln Feast.)
Hims is acquiring Zava to expand its offerings into international markets, specifically Germany and France.
Hims plans to fund the acquisition through cash on its balance sheet at the closing of the deal.
Hims announced it will cut about 4% of its workforce while still planning to hire for roles related to its long-term growth strategy.
Zava offers medical consultations and delivers prescription medicines, including popular weight-loss drugs like Mounjaro and Wegovy.
Hims plans to introduce personalized skincare, weight loss, and other healthcare offerings for patients in the new markets.
Explore more articles in the Finance category
